TY - JOUR
T1 - Delayed Obstruction With Asymptomatic Loss of Renal Function After Dextranomer/Hyaluronic Acid Copolymer (Deflux) Injection for Vesicoureteral Reflux
T2 - A Close Look at a Disturbing Outcome
AU - Papagiannopoulos, Dimitri
AU - Rosoklija, Ilina
AU - Cheng, Earl
AU - Yerkes, Elizabeth
PY - 2017/3/1
Y1 - 2017/3/1
N2 - Dextranomer/hyaluronic acid copolymer (Deflux) first received Food and Drug Administration approval in 2001 for endoscopic injection in children with grade II-IV vesicoureteral reflux VUR. As experience has grown, Deflux has been used more liberally with encouraging results. We report 3 cases where Deflux was used in off-label fashion, resulting in delayed ureteral obstruction and loss of renal function (range 18-52 months postoperatively). We now place increased emphasis on the need for long-term follow-up after Deflux in both routine and complex cases, particularly in situations of off-label use.
AB - Dextranomer/hyaluronic acid copolymer (Deflux) first received Food and Drug Administration approval in 2001 for endoscopic injection in children with grade II-IV vesicoureteral reflux VUR. As experience has grown, Deflux has been used more liberally with encouraging results. We report 3 cases where Deflux was used in off-label fashion, resulting in delayed ureteral obstruction and loss of renal function (range 18-52 months postoperatively). We now place increased emphasis on the need for long-term follow-up after Deflux in both routine and complex cases, particularly in situations of off-label use.
UR - http://www.scopus.com/inward/record.url?scp=85006736369&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85006736369&partnerID=8YFLogxK
U2 - 10.1016/j.urology.2016.09.013
DO - 10.1016/j.urology.2016.09.013
M3 - Article
C2 - 27687330
AN - SCOPUS:85006736369
SN - 0090-4295
VL - 101
SP - 63
EP - 66
JO - Urology
JF - Urology
ER -